July 27, 2026Pacing and Clinical Electrophysiology0 citations
View Full PaperEfficacy, Safety, and Procedural Outcomes of Pulsed‐Field Ablation for Paroxysmal Atrial Fibrillation: A Meta‐Analysis
Key Result
Pulsed-field ablation for paroxysmal atrial fibrillation yielded comparable arrhythmia recurrence rates to CF-RFA (23.90% vs 23.72%) and 2G-CBA (25.56%), with shorter procedure times than CF-RFA.
Key Points
- This research aims to evaluate the efficacy and safety of pulsed-field ablation (PFA) compared to other ablation methods for treating paroxysmal atrial fibrillation (pAF).
- Systematic literature review of studies comparing PFA, cryoballoon ablation, and radiofrequency ablation.
- Meta-analysis included 29 studies with 9 randomized controlled trials and 20 observational studies.
- Reported arrhythmia recurrence rates and procedure times using random-effects models.
- Arrhythmia recurrence rates were PFA 23.90%, CF-RFA 23.72%, and 2G-CBA 25.56%, with no significant differences.
- PFA procedure time was significantly shorter at 87.66 minutes compared to CF-RFA at 137.54 minutes.
- Overall complication rates were similar, but PFA had a lower phrenic nerve palsy incidence than 2G-CBA.
Study Design
Type
Meta-Analysis
Structured PICO
Does pulsed-field ablation reduce arrhythmia recurrence and complications compared to CF-RFA and 2G-CBA in patients with paroxysmal atrial fibrillation?
P
Population
Meta-analysis of 29 studies (9 randomized controlled trials and 20 observational studies) evaluating pulsed-field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation.
I
Intervention
Pulsed-field ablation (PFA)
C
Comparator
Second-generation cryoballoon ablation (2G-CBA) and contact force-sensing radiofrequency ablation (CF-RFA)
O
Outcome
Arrhythmia recurrence rates
Pulsed-field ablation demonstrates comparable efficacy and safety to established thermal ablation techniques for paroxysmal atrial fibrillation, with potentially shorter procedure times and lower risk of phrenic nerve palsy.
Main Result
Absolute Event Rate: 23.9% vs 23.72%
Abstract
ABSTRACT Introduction Pulsed‐field ablation (PFA) is a novel, nonthermal modality for the treatment of atrial fibrillation (AF) that may reduce procedural complications compared with conventional thermal ablation methods. Methods and Results A systematic literature review was conducted to identify studies comparing PFA with second‐generation cryoballoon ablation (2G‐CBA) and contact force‐sensing radiofrequency ablation (CF‐RFA) for paroxysmal AF (pAF) from the inception of PFA to January 2026. A single‐arm meta‐analysis was performed using random‐effects models, reporting the arcsine of the square root transformation (PAS) or mean (95% CI) for each intervention. Overall, 29 studies (9 randomized controlled trials and 20 observational studies) were included. Arrhythmia recurrence rates were comparable across all three interventions PFA: 23.90% (PAS 0.24, 95% CI 0.19–0.29, p < 0.0001); CF‐RFA: 23.72% (PAS 0.24, 95% CI 0.19–0.29, p < 0.0001); 2G‐CBA: 25.56% (PAS 0.26, 95% CI 0.20–0.31, p < 0.001). Overall procedure time was significantly shorter with PFA than with CF‐RFA and comparable to 2G‐CBA PFA: mean 87.66 min (95% CI 74.29–101.04, p < 0.001); CF‐RFA: mean 137.54 min (95% CI 123.65–151.43, p < 0.001); 2G‐CBA: mean 105.56 min (95% CI 89.93–121.18, p < 0.001). Fluoroscopy time was shorter with PFA than with 2G‐CBA but comparable to CF‐RFA PFA: mean 16.12 min (95% CI 12.36–19.88); CF‐RFA: mean 17.28 min (95% CI 13.59–20.98); 2G‐CBA: mean 22.08 min (95% CI 18.23–25.94). Overall complication rates did not differ significantly among the three interventions PFA: 2.93% (95% CI 1.87–4.22%); CF‐RFA: 3.66% (95% CI 1.84–6.07%); 2G‐CBA: 6.52% (95% CI 4.41–9.00%). The incidence of phrenic nerve palsy was significantly higher with 2G‐CBA than with PFA or CF‐RFA. Conclusion PFA demonstrated comparable efficacy and safety to CF‐RFA and 2G‐CBA, with a numerically shorter procedure time than CF‐RFA and a lower incidence of phrenic nerve palsy than 2G‐CBA, supporting PFA as a viable alternative to established ablation techniques for pAF.
Expert Takes3 quotes
1/3
“We are very pleased by the strong enrollment trajectory in the NANOPULSE-AF study. Reaching this midpoint milestone so quickly reflects the enthusiasm of our investigational sites for this technology and its potential to deliver leading durability in pulmonary vein isolation, procedural efficiency and consistent safe and effective patient outcomes.”